GlassScriptPhysician profile
Richard Pham
NPI 1710478607
$11,550.85
in general payments reported to CMS, 2019-2025
24 companies · $6,542 in 2025
The $6,542 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $243 · 2022: $395 · 2023: $799 · 2024: $3,573 · 2025: $6,542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,371 · Food and Beverage: $4,640 · Education: $903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,370.88 |
| Food and Beverage | $4,640.07 |
| Education | $902.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,177.44 | 2021-2025 | Amplia Mri Quad Crt-D Surescan, Micra, Selectsecure |
| Boston Scientific Corporation | $2,914.30 | 2024-2025 | Farapulse, General - Brady |
| Biosense Webster, INC. | $990.50 | 2025 | Carto 3 |
| Abbott Laboratories | $859.46 | 2023-2025 | Ensite, Aveir, Ensite Precision |
| Pfizer INC. | $299.04 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $274.68 | 2021-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $205.37 | 2022-2023 | Camzyos |
| Philips North America LLC | $190.46 | 2024 | (Bq9) Coronary Ivus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.86 | 2021-2023 | Jardiance |
| Lantheus Medical Imaging, INC. | $98.99 | 2021-2022 | |
| Medical Device Business Services, INC. | $93.66 | 2024 | Carto 3 |
| Amgen INC. | $55.43 | 2021-2024 | Repatha |
| Genzyme Corporation | $51.53 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.44 | 2022-2024 | Livtencity |
| Abiomed | $26.56 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $26.36 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $22.11 | 2023 | Verquvo |
| Edwards Lifesciences Corporation | $21.01 | 2025 | Sapien 3 Ultra Resilia |
| Astrazeneca Pharmaceuticals LP | $20.16 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $17.52 | 2024 | Opsumit |
| Atricure, INC. | $16.96 | 2023 | |
| Sanofi-Aventis U.S. LLC | $16.64 | 2023 | |
| Novo Nordisk INC | $16.58 | 2023 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $12.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.